• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Durable remissions in positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation.使用博纳吐单抗和干细胞移植治疗阳性急性淋巴细胞白血病的持久缓解。
Haematologica. 2019 Jun;104(6):e244-e247. doi: 10.3324/haematol.2018.210104. Epub 2019 Feb 14.
2
Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.复发/难治性B细胞前体急性淋巴细胞白血病儿科患者接受博纳吐单抗治疗后的生存率
Blood Cancer J. 2018 Aug 22;8(9):80. doi: 10.1038/s41408-018-0117-0.
3
Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.双特异性T细胞衔接器博纳吐单抗治疗B细胞急性淋巴细胞白血病的疗效、安全性及改善无白血病生存期的潜力
Expert Rev Hematol. 2017 Dec;10(12):1057-1067. doi: 10.1080/17474086.2017.1396890. Epub 2017 Nov 1.
4
Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.将免疫疗法纳入B细胞成人急性淋巴细胞白血病的治疗策略：博纳吐单抗和奥英妥珠单抗的作用
Am Soc Clin Oncol Educ Book. 2018 May 23;38:574-578. doi: 10.1200/EDBK_199505.
5
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.在一项关于博纳吐单抗治疗B系急性淋巴细胞白血病微小残留病患者的2期研究中的长期无复发生存率
Haematologica. 2017 Apr;102(4):e132-e135. doi: 10.3324/haematol.2016.153957. Epub 2017 Jan 12.
6
Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.Blinatumomab 治疗儿童复发/难治性 B 细胞前体急性淋巴细胞白血病。
Eur J Haematol. 2021 Apr;106(4):473-483. doi: 10.1111/ejh.13569. Epub 2021 Jan 11.
7
FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.FDA 批准：blinatumomab 用于伴有微小残留病灶的形态学缓解的 B 细胞前体急性淋巴细胞白血病患者。
Clin Cancer Res. 2019 Jan 15;25(2):473-477. doi: 10.1158/1078-0432.CCR-18-2337. Epub 2018 Sep 25.
8
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.免疫肿瘤学概念：用靶向 CD19 的双特异性 T 细胞衔接器疗法治疗 B 细胞恶性肿瘤。
Ann Hematol. 2020 Oct;99(10):2215-2229. doi: 10.1007/s00277-020-04221-0. Epub 2020 Aug 27.
9
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.儿童移植后复发/难治性B前体急性淋巴细胞白血病通过使用T细胞接合双特异性抗体博纳吐单抗治疗显示出持久缓解。
Haematologica. 2014 Jul;99(7):1212-9. doi: 10.3324/haematol.2013.100073. Epub 2014 Apr 11.
10
Safety and efficacy of blinatumomab: a real world data.真实世界数据评估blinatumomab 的安全性和疗效。
Ann Hematol. 2020 Apr;99(4):835-838. doi: 10.1007/s00277-019-03854-0. Epub 2020 Feb 20.

引用本文的文献

1
"A novel approach to understanding the role of TCF3 mutations in childhood B-cell precursor acute lymphoblastic leukemia".一种理解TCF3突变在儿童B细胞前体急性淋巴细胞白血病中作用的新方法
Transl Oncol. 2025 Aug 13;61:102505. doi: 10.1016/j.tranon.2025.102505.
2
Blinatumomab in pediatric B-acute lymphoblastic leukemia.博纳吐单抗治疗儿童B细胞急性淋巴细胞白血病
Front Immunol. 2025 Jul 23;16:1611701. doi: 10.3389/fimmu.2025.1611701. eCollection 2025.
3
Update on long-term outcomes of a cohort of patients with -positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantation.使用博纳吐单抗和干细胞移植治疗的一组阳性急性淋巴细胞白血病患者的长期预后最新情况。
Haematologica. 2025 Jun 1;110(6):1373-1378. doi: 10.3324/haematol.2024.286111. Epub 2025 Feb 6.
4
Unraveling the Genetic Heterogeneity of Acute Lymphoblastic Leukemia Based on NGS Applications.基于二代测序技术应用解析急性淋巴细胞白血病的遗传异质性
Cancers (Basel). 2024 Nov 26;16(23):3965. doi: 10.3390/cancers16233965.
5
[Clinical analysis of 7 cases of acute B cell lymphoblastic leukemia with t (17;19) (q21-22;p13)/TCF3-HLF fusion].7例伴t(17;19)(q21-22;p13)/TCF3-HLF融合的急性B淋巴细胞白血病临床分析
Zhonghua Xue Ye Xue Za Zhi. 2024 Sep 14;45(9):867-871. doi: 10.3760/cma.j.cn121090-20240220-00069.
6
Deciphering the role of HLF in idiopathic orbital inflammation: integrative analysis via bioinformatics and machine learning techniques.解析 HLF 在特发性眼眶炎症中的作用：基于生物信息学和机器学习技术的综合分析。
Sci Rep. 2024 Aug 20;14(1):19346. doi: 10.1038/s41598-024-68890-x.
7
Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation.急性淋巴细胞白血病中的威托克耐药性的特征是线粒体活性增加，并可通过靶向氧化磷酸化来克服。
Cell Death Dis. 2024 Jul 3;15(7):475. doi: 10.1038/s41419-024-06864-7.
8
Biological Markers of High-Risk Childhood Acute Lymphoblastic Leukemia.高危儿童急性淋巴细胞白血病的生物标志物
Cancers (Basel). 2024 Feb 21;16(5):858. doi: 10.3390/cancers16050858.
9
Novel Biomarkers and Molecular Targets in ALL.急性淋巴细胞白血病的新型生物标志物和分子靶点。
Curr Hematol Malig Rep. 2024 Feb;19(1):18-34. doi: 10.1007/s11899-023-00718-3. Epub 2023 Dec 4.
10
[Analysis on the clinical efficacy and adverse reactions of blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia].[博纳吐单抗治疗复发/难治性急性淋巴细胞白血病的临床疗效及不良反应分析]
Zhonghua Xue Ye Xue Za Zhi. 2023 Jun 14;44(6):516-519. doi: 10.3760/cma.j.issn.0253-2727.2023.06.015.

本文引用的文献

1
Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.复发/难治性B细胞前体急性淋巴细胞白血病儿科患者接受博纳吐单抗治疗后的生存率
Blood Cancer J. 2018 Aug 22;8(9):80. doi: 10.1038/s41408-018-0117-0.
2
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.加速儿科癌症药物研发： Venetoclax 治疗复发/难治性恶性肿瘤的新型 I 期研究设计。
Future Oncol. 2018 Sep;14(21):2115-2129. doi: 10.2217/fon-2018-0121. Epub 2018 Mar 29.
3
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.Blinatumomab 治疗 B 细胞前体急性淋巴细胞白血病成人患者的微小残留病。
Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22.
4
Redirecting T cells to hematological malignancies with bispecific antibodies.双特异性抗体引导 T 细胞靶向血液系统恶性肿瘤。
Blood. 2018 Jan 4;131(1):30-38. doi: 10.1182/blood-2017-06-741058. Epub 2017 Nov 8.
5
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.体外药物反应分析检测耐药急性淋巴细胞白血病中的复发性敏感性模式。
Blood. 2017 Mar 16;129(11):e26-e37. doi: 10.1182/blood-2016-09-738070. Epub 2017 Jan 25.
6
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.Blinatumomab 治疗儿童复发/难治性急性淋巴细胞白血病的 I/II 期研究。
J Clin Oncol. 2016 Dec 20;34(36):4381-4389. doi: 10.1200/JCO.2016.67.3301. Epub 2016 Oct 31.
7
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.致命性TCF3-HLF阳性急性淋巴细胞白血病的基因组学与药物谱分析确定了复发性突变模式及治疗选择。
Nat Genet. 2015 Sep;47(9):1020-1029. doi: 10.1038/ng.3362. Epub 2015 Jul 27.
8
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.Blinatumomab 治疗成人复发/难治性 B 前体急性淋巴细胞白血病患者的安全性和疗效：一项多中心、单臂、2 期研究。
Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16.
9
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.blinatumomab 治疗后细胞因子释放综合征与异常巨噬细胞活化有关，并通过细胞因子导向治疗得到改善。
Blood. 2013 Jun 27;121(26):5154-7. doi: 10.1182/blood-2013-02-485623. Epub 2013 May 15.
10
t(17;19) in Children with Acute Lymphocytic Leukemia: A Report of 3 Cases and a Review of the Literature.急性淋巴细胞白血病患儿的t(17;19)：3例报告及文献复习
Case Rep Hematol. 2013;2013:563291. doi: 10.1155/2013/563291. Epub 2013 Jan 3.

Durable remissions in positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation.

作者信息

Mouttet Brice, Vinti Luciana, Ancliff Philip, Bodmer Nicole, Brethon Benoît, Cario Gunnar, Chen-Santel Christiane, Elitzur Sarah, Hazar Volkan, Kunz Joachim, Möricke Anja, Stein Jerry, Vora Ajay, Yaman Yöntem, Schrappe Martin, Anak Sema, Baruche André, Locatelli Franco, von Stackelberg Arend, Stanulla Martin, Bourquin Jean-Pierre

机构信息

Pediatric Oncology, University Children's Hospital Zurich, Switzerland.

Department of Pediatric Haemato-Oncology, IRCCS Ospedale Bambino Gesù, Sapienza University of Rome, Italy.

出版信息

Haematologica. 2019 Jun;104(6):e244-e247. doi: 10.3324/haematol.2018.210104. Epub 2019 Feb 14.

DOI:10.3324/haematol.2018.210104
PMID:30765470
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6545832/
Abstract
摘要